Who are Vonoprazan+amoxicillin+clarithromycin 14 days's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vonoprazan+amoxicillin+clarithromycin 7 days.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vonoprazan-amoxicillin-clarithromycin-14-days.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Vonoprazan+amoxicillin+clarithromycin 14 days — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vonoprazan+amoxicillin+clarithromycin 14 days (Vonoprazan+amoxicillin+clarithromycin 14 days) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Proton pump inhibitor (vonoprazan) + beta-lactam antibiotic (amoxicillin) + macrolide antibiotic (clarithromycin). Area: G

marketed Proton pump inhibitor (vonoprazan) + beta-lactam antibiotic (amoxicillin) + macrolide antibiotic (clarithromycin) H+/K+-ATPase (vonoprazan); bacterial cell wall (amoxicillin); bacterial ribosome (clarithromycin) Gastroenterology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Vonoprazan+amoxicillin+clarithromycin 14 days (Vonoprazan+amoxicillin+clarithromycin 14 days) — Xijing Hospital of Digestive Diseases. This triple-therapy combination eradicates Helicobacter pylori by suppressing gastric acid with vonoprazan while amoxicillin and clarithromycin attack the bacteria directly.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vonoprazan+amoxicillin+clarithromycin 14 days TARGET	Vonoprazan+amoxicillin+clarithromycin 14 days	Xijing Hospital of Digestive Diseases	marketed	Proton pump inhibitor (vonoprazan) + beta-lactam antibiotic (amoxicillin) + macrolide antibiotic (clarithromycin)	H+/K+-ATPase (vonoprazan); bacterial cell wall (amoxicillin); bacterial ribosome (clarithromycin)
Vonoprazan+amoxicillin+clarithromycin 7 days	Vonoprazan+amoxicillin+clarithromycin 7 days	Xijing Hospital of Digestive Diseases	marketed	Proton pump inhibitor (vonoprazan) + beta-lactam antibiotic (amoxicillin) + macrolide antibiotic (clarithromycin)	H+/K+-ATPase (vonoprazan); bacterial cell wall and ribosome (amoxicillin and clarithromycin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Proton pump inhibitor (vonoprazan) + beta-lactam antibiotic (amoxicillin) + macrolide antibiotic (clarithromycin) class)

Xijing Hospital of Digestive Diseases · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vonoprazan+amoxicillin+clarithromycin 14 days — Competitive Intelligence Brief. https://druglandscape.com/ci/vonoprazan-amoxicillin-clarithromycin-14-days. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab